
zzso of tumor necrosis zzso zzso and zzso zzso demonstrate synergistic zzso activity in zzso zzso we initiated a clinical study of zzso zzso zzso and zzso combination therapy in zzso Twenty-five patients with zzso cancer received both zzso and zzso by intramuscular injection for 5 consecutive days every 2 weeks for a total of 4 zzso The dose levels were zzso zzso zzso zzso zzso zzso zzso zzso and zzso zzso per day of zzso A minimum of 2 patients were entered zzso at each dose zzso If the first zzso cycle of therapy was well zzso the dose was increased to the next highest dose level during the second zzso zzso zzso zzso and fatigue were observed at all zzso zzso of symptoms corresponded to increasing dose zzso Although zzso is identical to a zzso known as zzso the vast majority of our patients did not lose weight while on zzso However, zzso in zzso metabolism occurred and were zzso by a median change in zzso values of zzso zzso zzso zzso to zzso zzso and in cholesterol values of zzso zzso zzso zzso to zzso zzso The maximum tolerated dose was 75 zzso of zzso combined with 50 zzso of zzso with zzso side effects being mainly constitutional zzso A zzso suppression in zzso and zzso counts was zzso Hematologic parameters returned to baseline within 72 h after therapy was zzso and neither infection nor bleeding zzso Ten of 22 zzso patients had stable disease for a median of 8 weeks zzso zzso zzso 12 patients showed progressive zzso This study will form the framework for phase II trials of zzso and zzso combination zzso 

